<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">STAR Protoc</journal-id><journal-id journal-id-type="iso-abbrev">STAR Protoc</journal-id><journal-id journal-id-type="pmc-domain-id">3946</journal-id><journal-id journal-id-type="pmc-domain">starprot</journal-id><journal-title-group><journal-title>STAR Protocols</journal-title></journal-title-group><issn pub-type="epub">2666-1667</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491511</article-id><article-id pub-id-type="pmcid-ver">PMC12491511.1</article-id><article-id pub-id-type="pmcaid">12491511</article-id><article-id pub-id-type="pmcaiid">12491511</article-id><article-id pub-id-type="pmid">40944916</article-id><article-id pub-id-type="doi">10.1016/j.xpro.2025.104081</article-id><article-id pub-id-type="pii">S2666-1667(25)00487-3</article-id><article-id pub-id-type="publisher-id">104081</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Protocol for developing a melanoma brain metastasis mouse model for preclinical drug testing and brain tumor progression monitoring</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Almazan</surname><given-names initials="J">Jared</given-names></name><email>jared.almazan@hci.utah.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">4</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Turapov</surname><given-names initials="T">Tursun</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Holmen</surname><given-names initials="SL">Sheri L.</given-names></name><email>sheri.holmen@hci.utah.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn2" ref-type="fn">5</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>1</label>Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA</aff><aff id="aff2"><label>2</label>Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA</aff><aff id="aff3"><label>3</label>Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author <email>jared.almazan@hci.utah.edu</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author <email>sheri.holmen@hci.utah.edu</email></corresp><fn id="fn1"><label>4</label><p id="ntpara0010">Technical contact</p></fn><fn id="fn2"><label>5</label><p id="ntpara0015">Lead contact</p></fn></author-notes><pub-date pub-type="collection"><day>19</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><volume>6</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">491739</issue-id><elocation-id>104081</elocation-id><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><p>We present a protocol to generate a murine model of established melanoma brain metastases by intracranially injecting tumor cells into newborn &#8220;glowing head&#8221; C57BL/6 syngeneic mice, which are tolerized to both GFP and luciferase. First, we describe steps for cell and animal preparation. We then detail the utilization of bioluminescent imaging to monitor brain tumor progression. This model enables the evaluation of therapeutic efficacy against established melanoma brain metastases.</p><p>For complete details on the use and execution of this protocol, please refer to Almazan et al.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fx1.jpg"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">Develop a murine model of melanoma brain metastases for preclinical drug testing</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Intracranial injections into newborn mice to induce melanoma brain metastases</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Detection of brain tumor growth and progression using bioluminescent imaging</p></list-item></list></p></abstract><abstract abstract-type="editor-highlights" id="abs0025"><p>Publisher&#8217;s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.</p></abstract><abstract abstract-type="teaser" id="abs0030"><p>We present a protocol to generate a murine model of established melanoma brain metastases by intracranially injecting tumor cells into newborn &#8220;glowing head&#8221; C57BL/6 syngeneic mice, which are tolerized to both GFP and luciferase. First, we describe steps for cell and animal preparation. We then detail the utilization of bioluminescent imaging to monitor brain tumor progression. This model enables the evaluation of therapeutic efficacy against established melanoma brain metastases.</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>Cancer</kwd><kwd>Health Sciences</kwd><kwd>Model Organisms</kwd><kwd>Molecular Biology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Before you begin</title><p id="p0025">Melanoma is one of the deadliest forms of skin cancer, with brain metastases being the major cause of treatment failure.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> To address this issue and evaluate the effects of drug treatments on established brain metastases, this protocol outlines the steps for generating a murine model of melanoma brain metastases using GFP and luciferase-expressing syngeneic YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells in newborn &#8220;glowing head&#8221; C57BL/6 mice.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p><p id="p0030">The expression of GFP in this modified cell line has the advantage of confirming delivery of the virus harboring AKT1<sup>E17K</sup> and luciferase, with the latter being essential for the bioluminescent imaging (BLI) technique. Additionally, this cell line expresses BRAF<sup>V600E</sup>, which activates the MAPK pathway, and expresses AKT1<sup>E17K</sup> in the context of <italic toggle="yes">Cdkn2a</italic> and <italic toggle="yes">Pten</italic> loss, resulting in activation of the PI3K/AKT signaling pathway, which is a common occurrence in human melanoma. Furthermore, we have previously demonstrated that PI3K/AKT pathway activation in this context is required for melanoma cell growth in the brain.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p><p id="p0035">This protocol also takes advantage of the immunocompetent &#8220;glowing head&#8221; C57BL/6 mice engineered by Day et al., as this mouse strain is tolerized to both GFP and luciferase.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Additionally, the albino phenotype of these mice reduces the effects of autofluorescence. For this model, we intracranially inject 30 YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells into newborn mice, as previous pilot studies with injections of 1000 and 100 cells resulted in early mortality, thus prompting the use of a smaller number of cells. Furthermore, newborn mice are utilized because their skull is softer and injections can be done with a gas tight Hamilton syringe without the need for a stereotactic injection device. Lastly, bioluminescent imaging will be used to detect the establishment and colonization of the cell line in the brain, as well as monitor tumor burden over time.</p><p id="p0040">Various models have been developed to study melanoma, including zebrafish models for melanoma development and drug screening, and patient-derived xenografts for assessing drug resistance and treatment efficacy.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> However, there is a lack of preclinical models that replicate the brain metastatic patterns seen in patients. Our model utilizes an engineered melanoma cell line that closely mimics human brain metastases and enables direct induction of tumors into the brains of immunocompetent mice. Therefore, the generation of this model facilitates efficient modeling of melanoma brain metastases for preclinical drug studies.</p><sec id="sec1.1"><title>Institutional permissions</title><p id="p0045">All experiments performed on animal models were approved by the institutional animal care and use committee (IACUC) at the University of Utah. Please obtain all permissions needed for the use of animal models from proper authorities before performing any experiments or procedures on live animals.</p></sec><sec id="sec1.2"><title>Cell culture preparation</title><p id="p0050">
<disp-quote id="disp0010"><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fx2.gif"/><bold>Timing: 1&#8211;3 days</bold></p></disp-quote>
<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0055">Thaw the GFP and luciferase-expressing YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells and culture them in Dulbecco&#8217;s Modified Eagle Medium (DMEM)/F-12 supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% Minimum Essential Medium (MEM) Non-Essential Amino Acids Solution in a 10 cm tissue culture dish.</p></list-item><list-item id="o0015"><label>2.</label><p id="p0060">Maintain cells in culture at 37&#176;C with 5% CO<sub>2</sub> for 1&#8211;3 days.</p></list-item><list-item id="o0020"><label>3.</label><p id="p0065">Prepare for the injection when the preferred confluency is achieved.</p></list-item><list-item id="o0025"><label>4.</label><p id="p0070">Using a fluorescence microscope, confirm the presence of GFP expression in the cells as shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>. Successful GFP expression also confirms the presence of luciferase in the cell line, which is crucial in the upcoming steps of the protocol. Furthermore, a luciferase assay may be performed to confirm luciferase activity in the cell line.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>GFP expression in the YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells</p><p>(A and B) Using a fluorescence microscope, GFP expression is confirmed in the cell line (A) with the GFP filter (B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></list-item></list>
<disp-quote id="disp0015"><p><bold><italic toggle="yes">Note:</italic></bold> We recommend achieving approximately 80% cell confluency prior to cell injection, as over confluency can compromise the viability of the cells.</p></disp-quote>
</p></sec></sec><sec id="sec2"><title>Key resources table</title><p id="p0075">
<table-wrap position="float" id="undtbl1" orientation="portrait"><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">REAGENT or RESOURCE</th><th colspan="1" rowspan="1">SOURCE</th><th colspan="1" rowspan="1">IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">DMEM/F-12, HEPES</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">11330057</td></tr><tr><td colspan="1" rowspan="1">Trypsin-EDTA (0.05%), phenol red</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">25300120</td></tr><tr><td colspan="1" rowspan="1">Fetal bovine serum</td><td colspan="1" rowspan="1">Atlas Biologicals Inc.</td><td colspan="1" rowspan="1">F-0500-DR</td></tr><tr><td colspan="1" rowspan="1">Penicillin-streptomycin (10,000 U/mL)</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">15140122</td></tr><tr><td colspan="1" rowspan="1">MEM non-essential amino acids solution (100X)</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">11140050</td></tr><tr><td colspan="1" rowspan="1">Isoflurane inhalation solution 99.9%</td><td colspan="1" rowspan="1">McKesson Medical-Surgical, Inc.</td><td colspan="1" rowspan="1">803250</td></tr><tr><td colspan="1" rowspan="1">PBS, pH 7.4</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">10010023</td></tr><tr><td colspan="1" rowspan="1">D-luciferin, potassium salt</td><td colspan="1" rowspan="1">Gold Biotechnology Inc.</td><td colspan="1" rowspan="1">LUCK-2G</td></tr><tr><td colspan="1" rowspan="1">HBSS, calcium, magnesium, no phenol red</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">14025134</td></tr><tr><td colspan="1" rowspan="1">Trypan blue stain</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="T10282">T10282</ext-link></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="3" rowspan="1"><bold>Experimental models: Cell lines</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">YUMM3.2 (PTEN<sup>&#8722;/&#8722;</sup>, Akt1<sup>E17K</sup>, luciferase, EGFP)</td><td colspan="1" rowspan="1">Almazan et al.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="3" rowspan="1"><bold>Experimental models: Organisms/strains</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">C57BL/6-<italic toggle="yes">Tyr</italic><sup><italic toggle="yes">c-Brd</italic></sup> Tg(Gh1-luc/EGFP) D8Mrln/J; C57BL/6 glowing head</td><td colspan="1" rowspan="1">Day et al.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>; The Jackson Laboratory</td><td colspan="1" rowspan="1">Strain #027662</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="3" rowspan="1"><bold>Software and algorithms</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">Living Image Software</td><td colspan="1" rowspan="1">Revvity</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.revvity.com/software-downloads/in-vivo-imaging" id="intref0010">https://www.revvity.com/software-downloads/in-vivo-imaging</ext-link></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="3" rowspan="1"><bold>Other</bold></td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">Thermo Fisher Countess II automated cell counter</td><td colspan="1" rowspan="1">Marshall Scientific</td><td colspan="1" rowspan="1">I-CACC2</td></tr><tr><td colspan="1" rowspan="1">Countess cell counting chamber slide</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="C10228">C10228</ext-link></td></tr><tr><td colspan="1" rowspan="1">IVIS spectrum <italic toggle="yes">in vivo</italic> imaging system</td><td colspan="1" rowspan="1">Revvity</td><td colspan="1" rowspan="1">CLS158738</td></tr><tr><td colspan="1" rowspan="1">Gas-tight Hamilton syringe</td><td colspan="1" rowspan="1">Hamilton Company</td><td colspan="1" rowspan="1">80075</td></tr><tr><td colspan="1" rowspan="1">EVOS FL fluorescence microscope</td><td colspan="1" rowspan="1">Thermo Fisher Scientific</td><td colspan="1" rowspan="1">AMF4300</td></tr><tr><td colspan="1" rowspan="1">Olympus CKX53-BSC tissue culture inverted microscope</td><td colspan="1" rowspan="1">Evident Scientific</td><td colspan="1" rowspan="1">CKX53-BSC</td></tr><tr><td colspan="1" rowspan="1">Easy Touch U-100 insulin syringe with needle, 25G 1 cc 1/2 in (12.7 mm)</td><td colspan="1" rowspan="1">Amazon</td><td colspan="1" rowspan="1">N/A</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec3"><title>Step-by-step method details</title><sec id="sec3.1"><title>Preparation of cells for intracranial injection</title><p id="p0080">
<disp-quote id="disp0020"><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fx2.gif"/><bold>Timing: 45 min</bold></p></disp-quote>
</p><p id="p0085">This step prepares tumor cells for injection with the desired cell density and volume.<list list-type="simple" id="olist0015"><list-item id="o0030"><label>1.</label><p id="p0090">Remove the media from the 10 cm tissue culture dish of &#8764;80% confluent cells with gentle aspiration.<list list-type="simple" id="olist0020"><list-item id="o0035"><label>a.</label><p id="p0095">Wash cells once in 1 &#215; PBS.</p></list-item><list-item id="o0040"><label>b.</label><p id="p0100">Add 1 mL of 0.05% Trypsin-EDTA and swirl the tissue culture dish to completely cover the cells.</p></list-item><list-item id="o0045"><label>c.</label><p id="p0105">Incubate the tissue culture dish at 37&#176;C for 5&#8211;7 min.</p></list-item><list-item id="o0050"><label>d.</label><p id="p0110">Check under the microscope to see if the cells have detached from the tissue culture dish.</p></list-item></list></p></list-item></list><disp-quote id="disp0025"><p><bold><italic toggle="yes">Note:</italic></bold> It is critical to ensure that all the cells have detached from the plate before proceeding to the next step.</p></disp-quote><list list-type="simple" id="olist0025"><list-item id="o0055"><label>2.</label><p id="p0115">Add 5 mL of media to stop the Trypsin-EDTA reaction.<list list-type="simple" id="olist0030"><list-item id="o0060"><label>a.</label><p id="p0120">Rinse the media over the tissue culture dish several times to ensure that all the cells have been collected from the plate.</p></list-item><list-item id="o0065"><label>b.</label><p id="p0125">Transfer the cells into a sterile 15 mL conical tube.</p></list-item><list-item id="o0070"><label>c.</label><p id="p0130">Centrifuge the cells for 4 min at 400 &#215; <italic toggle="yes">g</italic> at room temperature (RT).</p></list-item><list-item id="o0075"><label>d.</label><p id="p0135">Remove the supernatant with gentle aspiration.</p></list-item><list-item id="o0080"><label>e.</label><p id="p0140">Gently resuspend the cell pellet in 1 mL of fresh media.</p></list-item></list></p></list-item><list-item id="o0085"><label>3.</label><p id="p0145">Determine the cell concentration using a Countess II Automated Cell Counter per the manufacturer&#8217;s specifications. In this step, the cell viability and cell concentration are measured.<list list-type="simple" id="olist0035"><list-item id="o0090"><label>a.</label><p id="p0150">In a sterile microcentrifuge tube, add 10 &#956;L of 0.4% Trypan Blue stain.</p></list-item><list-item id="o0095"><label>b.</label><p id="p0155">Resuspend and transfer 10 &#956;L of the cell suspension from Step 2 into the same tube with the Trypan Blue.</p></list-item><list-item id="o0100"><label>c.</label><p id="p0160">Resuspend to mix the Trypan Blue with the cell suspension.</p></list-item><list-item id="o0105"><label>d.</label><p id="p0165">Transfer 10 &#956;L from the mixture into a chamber of a countess cell counting chamber slide.</p></list-item><list-item id="o0110"><label>e.</label><p id="p0170">Insert the slide into the Countess II Automated Cell Counter and quantify the concentration of live cells in the cell suspension.</p></list-item><list-item id="o0115"><label>f.</label><p id="p0175">Record the live cell concentration.</p></list-item></list></p></list-item></list><disp-quote id="disp0030"><p><bold><italic toggle="yes">Note:</italic></bold> Manual counting with a hemocytometer is an alternative method to determine the cell concentration if an automated counter is not available.</p></disp-quote><list list-type="simple" id="olist0040"><list-item id="o0120"><label>4.</label><p id="p0180">Determine the volume of cells required to inject 30 cells into each newborn mouse.<disp-quote id="disp0035"><p><bold><italic toggle="yes">Note:</italic></bold> The calculations in this preparation step are designed to resuspend the cells in a final volume of 10 mL (demonstrated in steps 4 and 5), as using a larger volume ensures the accurate delivery of the intended number of cells to reliably induce brain metastases.</p></disp-quote><list list-type="simple" id="olist0045"><list-item id="o0125"><label>a.</label><p id="p0185">Calculate the volume of cell suspension needed to inject 30 cells per mouse.<disp-quote id="disp0040"><p><bold><italic toggle="yes">Note:</italic></bold> For example, live cell concentration = 8.67 &#215; 10<sup>6</sup> cells/mL.</p></disp-quote><list list-type="simple" id="olist0050"><list-item id="o0130"><label>i.</label><p id="p0190">10 mL of cell suspension = 10,000 &#956;L.</p><p id="p0195">&#160;&#160;&#160;10 cells per &#956;L density.</p><p id="p0200">&#160;&#160;&#160;Each mouse is injected with 30 cells (3 &#956;L = 30 cells).</p></list-item><list-item id="o0135"><label>ii.</label><p id="p0205">Perform calculations to obtain 100,000 cells:</p><p id="p0210">&#160;&#160;&#160;10,000 &#956;L &#215; <inline-formula><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.25em"/><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi>&#956;</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> = 100,000 cells.</p><p id="p0215">&#160;&#160;&#160;100,000 cells &#215; <inline-formula><mml:math id="M2" altimg="si2.gif"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi>m</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mn>8.64</mml:mn><mml:mspace width="0.25em"/><mml:mi>x</mml:mi><mml:mspace width="0.25em"/><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup><mml:mspace width="0.25em"/><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> = 0.01157 mL = <bold>11.57 &#956;L.</bold></p><p id="p0220">&#160;&#160;&#160;<bold>11.57 &#956;L</bold> = 100,000 cells (this volume will be transferred into a final volume of 10 mL in the next step).</p><p id="p0225">&#160;&#160;&#160;3 &#956;L = 30 cells.</p></list-item></list></p></list-item></list></p></list-item><list-item id="o0140"><label>5.</label><p id="p0230">Wash and prepare the cells for injection.<list list-type="simple" id="olist0060"><list-item id="o0145"><label>a.</label><p id="p0235">Transfer the volume calculated from the previous step into a 1.5 mL microcentrifuge tube.</p></list-item><list-item id="o0150"><label>b.</label><p id="p0240">Add 100 &#956;L of 1&#215; HBSS into the tube and resuspend.</p></list-item><list-item id="o0155"><label>c.</label><p id="p0245">Transfer the resuspended cells into a 15 mL conical tube with &#8764;5&#8211;10 mL of 1X HBSS and spin down the tube for 2 min at 450 g at RT.</p></list-item><list-item id="o0160"><label>d.</label><p id="p0250">Gently aspirate the supernatant and resuspend the pellet in 100 &#956;L of 1&#215; HBSS.</p></list-item><list-item id="o0165"><label>e.</label><p id="p0255">Add &#8764;5&#8211;10 mL of 1X HBSS and repeat the spin down as previously described.</p></list-item><list-item id="o0170"><label>f.</label><p id="p0260">Gently aspirate the supernatant and resuspend the pellet in 100 &#956;L of 1&#215; HBSS but then transfer the cell suspension into a 15 mL conical tube with 9900 &#956;L of 1X HBSS. Vortex and invert afterward.</p></list-item><list-item id="o0175"><label>g.</label><p id="p0265">Transfer 5 mL of the cell suspension into a clean 5 mL Eppendorf tube and immediately place the tube on ice.</p></list-item><list-item id="o0180"><label>h.</label><p id="p0270">Prepare two 1.5 mL microcentrifuge tubes for the following step. One tube with 1 mL of 1X HBSS, and the other with 1 mL of 70% EtOH.</p></list-item></list></p></list-item></list></p></sec><sec id="sec3.2"><title>Intracranial injection into newborn &#8220;glowing head&#8221; C57BL/6 mice</title><p id="p0275">
<disp-quote id="disp0045"><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fx2.gif"/><bold>Timing: 5&#8211;7 min per mouse</bold></p></disp-quote>
</p><p id="p0280">This step describes the injection process into newborn &#8220;glowing head&#8221; C57BL/6 mice. Newborn mice can be injected ranging from postnatal Day 0&#8211;Day 3.<list list-type="simple" id="olist0065"><list-item id="o0185"><label>6.</label><p id="p0285">Clean the gas-tight Hamilton syringe prior to each injection.<list list-type="simple" id="olist0070"><list-item id="o0190"><label>a.</label><p id="p0290">Using the Hamilton syringe, draw up 70% EtOH from the 1.5 mL microcentrifuge tube and eject it back into the tube. Repeat this multiple times.</p></list-item><list-item id="o0195"><label>b.</label><p id="p0295">Repeat the previous step but with the 1.5 mL microcentrifuge tube containing 1 &#215; HBSS.</p></list-item></list></p></list-item><list-item id="o0200"><label>7.</label><p id="p0300">Inject the newborn pups with the GFP and luciferase-expressing YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells.<list list-type="simple" id="olist0080"><list-item id="o0205"><label>a.</label><p id="p0305">While wearing gloves, place a drop of the 70% EtOH on the top of the head of the newborn pup to sterilize the area.</p></list-item><list-item id="o0210"><label>b.</label><p id="p0310">With the empty Hamilton syringe, slowly draw up 3 &#956;L (30 cells) from the cell suspension in Step 5.</p></list-item><list-item id="o0215"><label>c.</label><p id="p0315">On a flat surface, gently hold the pup around the shoulder area and insert the syringe into the skull 2-mm ventral and anterior to lambda (intersection of the lambdoid and sagittal sutures) as shown in <xref rid="fig2" ref-type="fig">Figure 2</xref>.<disp-quote id="disp0050"><p><bold><italic toggle="yes">Note:</italic></bold> Insert the syringe into the injection site at a depth of halfway through the thin portion (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p></disp-quote><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Dorsal view of a newborn mouse</p><p>This figure shows the location of the injection site in reference to lambda and bregma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0320"><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Image of a gas-tight Hamilton syringe used for intracranial injections</p><p>The thin portion of the syringe is indicated along with the depth of the injection (red arrow).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></list-item><list-item id="o0220"><label>d.</label><p id="p0325">Slowly inject the cells into the skull by pressing down on the plunger. Hold the needle in place for &#8764;3 seconds and then slowly retract the needle.</p></list-item><list-item id="o0225"><label>e.</label><p id="p0330">Between each injection, repeat the wash steps for the Hamilton syringe as previously described in Step 6.</p></list-item></list></p></list-item></list></p></sec><sec id="sec3.3"><title>Assess brain tumor formation with bioluminescent imaging</title><p id="p0335">
<disp-quote id="disp0055"><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fx2.gif"/><bold>Timing: 15 min per cage</bold></p></disp-quote>
</p><p id="p0340">This step confirms and measures brain tumor growth via BLI. Once a signal is detected, the mice can be enrolled into preclinical drug studies to evaluate the efficacy of various drug treatments in suppressing established melanoma brain metastases.</p><p id="p0345">Duration: Weekly until the experimental endpoint is reached.<list list-type="simple" id="olist0085"><list-item id="o0230"><label>8.</label><p id="p0350">Gather all the necessary materials including insulin syringes, D-Luciferin (16.7 mg/mL), bucket of ice, flash drive, and paper towels.</p></list-item><list-item id="o0235"><label>9.</label><p id="p0355">Thaw D-Luciferin on ice for 10-20 min.</p></list-item></list><disp-quote id="disp0060"><p><bold><italic toggle="yes">Note:</italic></bold> Once thawed, keep the D-luciferin on ice and protect it from light. This can be done by covering the ice bucket, using light-protected microcentrifuge tubes, or wrapping the tube in tinfoil.</p></disp-quote><list list-type="simple" id="olist0090"><list-item id="o0240"><label>10.</label><p id="p0360">Turn on and set up the IVIS Spectrum In Vivo Imaging System per the manufacturer&#8217;s specifications.<list list-type="simple" id="olist0095"><list-item id="o0245"><label>a.</label><p id="p0365">Open the Living Image software.</p></list-item><list-item id="o0250"><label>b.</label><p id="p0370">Log into the user account.</p></list-item><list-item id="o0255"><label>c.</label><p id="p0375">Turn on the oxygen concentrator and isoflurane vaporizer to initiate the flow of oxygen and anesthetic into the induction chamber. Prepare the nose cones inside the pre-heated animal imaging platform in the IVIS chamber.<list list-type="simple" id="olist0100"><list-item id="o0260"><label>i.</label><p id="p0380">Adjust the flow rate of isoflurane to be at 2.5 v/v.</p></list-item><list-item id="o0265"><label>ii.</label><p id="p0385">Adjust the oxygen flow rate to 2 L/min.</p></list-item></list></p></list-item><list-item id="o0270"><label>d.</label><p id="p0390">Click on &#8220;Initialize&#8221; to warm-up the IVIS system.<list list-type="simple" id="olist0105"><list-item id="o0275"><label>i.</label><p id="p0395">Initializing is finished once the temperature bar turns from red to green.</p></list-item></list></p></list-item><list-item id="o0280"><label>e.</label><p id="p0400">Set up the Field of View.<list list-type="simple" id="olist0110"><list-item id="o0285"><label>i.</label><p id="p0405">For whole-body BLI, choose &#8220;D&#8221;. For <italic toggle="yes">ex vivo</italic> organ BLI, choose &#8220;C&#8221;.</p></list-item></list></p></list-item><list-item id="o0290"><label>f.</label><p id="p0410">Set exposure time to &#8220;Auto&#8221; and keep the Subject Height at 1.50 cm.</p></list-item><list-item id="o0295"><label>g.</label><p id="p0415">Check the Luminescent and Photograph boxes in Imaging Mode.</p></list-item><list-item id="o0300"><label>h.</label><p id="p0420">Final set up of the control panel is shown in <xref rid="fig4" ref-type="fig">Figure 4</xref>.<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Image of the control panel for the Living Image software</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></list-item></list></p></list-item><list-item id="o0305"><label>11.</label><p id="p0425">The mice are first imaged upon weaning (day 21).</p></list-item><list-item id="o0310"><label>12.</label><p id="p0430">Place the mice in the induction chamber with 2.5% isoflurane and 2 L/min oxygen for &#8764;5 min for the mice to be anesthetized.</p></list-item><list-item id="o0315"><label>13.</label><p id="p0435">After the mice have been anesthetized, inject 100 &#956;L of D-Luciferin intraperitoneally into each mouse.</p></list-item></list><disp-quote id="disp0065"><p><bold><italic toggle="yes">Note:</italic></bold> If bubbles appear in the syringe from drawing up the D-Luciferin, tap the syringe and slowly dispense the solution to eliminate the air. Repeat until no bubbles are present in the syringe.</p></disp-quote><disp-quote id="disp0070"><p><bold><italic toggle="yes">Note:</italic></bold> After the intraperitoneal injections, transfer the mice to a pre-heated animal imaging platform inside the IVIS chamber and maintain anesthesia via the nose cone.</p></disp-quote><list list-type="simple" id="olist0115"><list-item id="o0320"><label>14.</label><p id="p0440">Acquire bioluminescent images at 10 min post-injection.<list list-type="simple" id="olist0120"><list-item id="o0325"><label>a.</label><p id="p0445">Click on &#8220;Acquire&#8221; in the control panel to image the mice.</p></list-item></list></p></list-item></list><disp-quote id="disp0075"><p><bold><italic toggle="yes">Note:</italic></bold> Space the mice at least one nose cone distance away from one another to prevent interfering bioluminescence. An alternative is to use dividers between each mouse.</p></disp-quote><list list-type="simple" id="olist0125"><list-item id="o0330"><label>15.</label><p id="p0450">Quantify the bioluminescence signal of each mouse.<list list-type="simple" id="olist0130"><list-item id="o0335"><label>a.</label><p id="p0455">In the captured image, set the count to Radiance.</p></list-item><list-item id="o0340"><label>b.</label><p id="p0460">In the Tool Palette pop-up, select &#8220;ROI Tools&#8221;, and place an ROI (region of interest) box around the head area each mouse (site of which the tumor will develop) and click on &#8220;Acquire&#8221;. This quantifies the signal with radiance (p/sec/cm<sup>2</sup>/sr) (<xref rid="fig5" ref-type="fig">Figure 5</xref>).<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Representative BLI of 5-week-old &#8220;glowing head&#8221; C57BL/6 mouse with a brain tumor undergoing targeted therapy</p><p>An ROI box is placed around the head of the mouse and the BLI signal is quantified with radiance. Upon quantification, the BLI signal of the mouse in this figure is 18,310 radiance (p/sec/cm<sup>2</sup>/sr).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></list-item></list></p></list-item></list><disp-quote id="disp0080"><p><bold><italic toggle="yes">Note:</italic></bold> Radiance is preferred over total flux, as it normalizes both the surface area and bioluminescent signal intensity, thereby enabling more accurate longitudinal comparisons of data from the same animal.</p></disp-quote><list list-type="simple" id="olist0135"><list-item id="o0345"><label>16.</label><p id="p0465">After image acquisition, transfer the mice back to their cage and monitor for recovery from anesthesia.</p></list-item></list><disp-quote id="disp0085"><p><bold><italic toggle="yes">Note:</italic></bold> The mice will awaken and mobilize within a few minutes.</p></disp-quote><list list-type="simple" id="olist0140"><list-item id="o0350"><label>17.</label><p id="p0470">The mice can be imaged weekly (timing varies for what is appropriate for the proposed study) for a predetermined number of days to evaluate the effects of the drug treatment on established melanoma brain metastases.</p></list-item></list><disp-quote id="disp0090"><p><bold><italic toggle="yes">Note:</italic></bold> Once a BLI signal is detected (&#8764;21 days of age), the mice can be enrolled into preclinical drug studies and may receive treatment via oral gavage, intravenous (IV) injection, and/or intraperitoneal injections.</p></disp-quote></p></sec></sec><sec id="sec4"><title>Expected outcomes</title><p id="p0475">This protocol describes the development of a murine model of established melanoma brain metastases. Following the completion of this protocol, the YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells will successfully grow in the brain, and 100% of the mice will develop a BLI signal in the brain (<xref rid="fig5" ref-type="fig">Figure 5</xref>). It is anticipated that the mice in this model will develop a BLI signal by weaning (day 21); however, in rare cases, some mice may require additional days post-weaning to exhibit a BLI signal. Subsequent imaging after approximately three days can provide more time for tumor cell detection.</p><p id="p0480">Additionally, the BLI signal correlates with brain tumor growth as assessed histologically after necropsy, as shown in <xref rid="fig6" ref-type="fig">Figure 6</xref>. Once a BLI signal is detected, it is crucial to initiate the proposed preclinical drug study immediately, as the mice begin to decline rapidly with brain tumor growth. Signs of declining health may include heavy breathing, squinting eyes, running in circles, ungroomed fur, and lack of mobility.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Representative images of the growth of the YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cells in the brain</p><p>(A&#8211;C) Images of a whole-body BLI (A), ex vivo BLI following euthanasia that confirms the successful growth of the cells in the brain (B), and an H&amp;E stain on the brain tissue with the tumor cells indicated by the dashed box (C).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0485">This model was designed to mimic clinical cases of established melanoma brain metastases and to evaluate the efficacy of treatment combinations in suppressing metastatic brain tumor growth. Compounds that successfully attenuated tumor growth in the brain and prolonged survival in this model include the FAK inhibitor VS-4718 and the RAF/MEK clamp avutometinib in combination.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Other treatment strategies have yet to be evaluated in this model.</p></sec><sec id="sec5"><title>Limitations</title><p id="p0490">A limitation of this model is that it does not fully represent the biology of all melanoma patients with established brain metastases, as this model is driven by mutant BRAF in the context of Akt1<sup>E17K</sup> along with <italic toggle="yes">Pten</italic> and <italic toggle="yes">Cdkn2a</italic> loss. Consequently, preclinical studies that evaluate treatment strategies against other melanoma subtypes &#8211; such as those with mutant NRAS, NF1 loss, or triple wild-type have yet to be tested in this context. Furthermore, BLI in this protocol only measures luminescence exclusively from the melanoma cells injected intracranially and monitors changes longitudinally. We suggest incorporating additional techniques such as magnetic resonating imaging (MRI) alongside BLI and histological analysis of the tissue, if the precise localization of cells, tumor volume, and tumor characteristics are critical to the study. Lastly, this model specifically represents brain metastases originating from cutaneous melanoma and has not been tested on cells from uveal or mucosal melanoma.</p></sec><sec id="sec6"><title>Troubleshooting</title><sec id="sec6.1"><title>Problem 1</title><p id="p0495">Mice do not survive up to weaning (Day 21).</p></sec><sec id="sec6.2"><title>Potential solution</title><p id="p0500">If the mice do not survive up to the weaning date, this can be due to several reasons. As previously mentioned, an injection of 30 cells was determined due to the aggressiveness of the cell line; injecting a higher number of cells may lead to early mortality. Injecting 30 cells was sufficient to allow survival up to 4 weeks. This highlights the importance of accurately counting the viable melanoma cells and using calibrated instruments. To ensure accurate cell counts, gently resuspend and/or invert the tube several times before quantification. Avoid inverting too quickly since this may lead to air bubble formation. Additionally, it is possible that the injection was performed too deep. Therefore, it is crucial to inject the syringe only 2 mm ventral to bregma as shown in <xref rid="fig3" ref-type="fig">Figure 3</xref>.</p></sec><sec id="sec6.3"><title>Problem 2</title><p id="p0505">The mice do not produce a BLI signal upon weaning.</p></sec><sec id="sec6.4"><title>Potential solution</title><p id="p0510">If the mice do not produce a signal at weaning, one explanation is that they could be positioned too closely during imaging in the IVIS system. As previously mentioned, spacing the mice at least one nose-cone distance apart prevents interfering bioluminescent signals that might obscure the signal from other mice. An example of proper mouse spacing is shown in <xref rid="fig7" ref-type="fig">Figure 7</xref>. If it is necessary to use all of the nose-cone slots in the IVIS chamber, dividers can be added between each mouse to reduce signal interference.<fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>Mouse placement in the IVIS chamber</p><p>Representative image of proper spacing (at least one nose-cone distance apart) of the mice to prevent interfering bioluminescent signals. An alternative strategy is to use dividers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0515">It is also critical to image the mice 10 minutes post-intraperitoneal injection of luciferin, as described in the protocol, due to the time required for the substrate to reach the tumor cells. In rare instances, the mice may require an additional few days to produce a detectable BLI signal. If a mouse does not produce a signal on day 21 (weaning), repeat the BLI after three days to allow more time for the tumor cells to be detected.</p></sec></sec><sec id="sec7"><title>Resource availability</title><sec id="sec7.1"><title>Lead contact</title><p id="p0520">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Sheri Holmen (<email>sheri.holmen@hci.utah.edu</email>).</p></sec><sec id="sec7.2"><title>Technical contact</title><p id="p0525">Technical questions on executing this protocol should be directed to and will be answered by the technical contact, Jared Almazan (<email>jared.almazan@hci.utah.edu</email>).</p></sec><sec id="sec7.3"><title>Materials availability</title><p id="p0530">The YUMM3.2;Pten&#8722;/&#8722;;Akt1<sup>E17K</sup> melanoma cell line utilized throughout the protocol was engineered by members of the Holmen lab through modification of isogenic YUMM3.2 cells. For access to this cell line, please contact Jared Almazan or Dr. Sheri Holmen.</p></sec><sec sec-type="data-availability" id="sec7.4"><title>Data and code availability</title><p id="p0535">This study did not generate or analyze datasets or code.</p></sec></sec><sec id="sec8"><title>Acknowledgments</title><p id="p0540">The work was supported by the funds provided by the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010637</institution-id><institution>Huntsman Cancer Foundation</institution></institution-wrap></funding-source> and grants from the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> (NIH) (<award-id award-type="grant" rid="gs2">R01CA121118</award-id>). We thank the Precision Cancer Models (PCM) Shared Resource at Huntsman Cancer Institute at the University of Utah for allowing our lab to utilize the IVIS spectrum <italic toggle="yes">in vivo</italic> imaging system for these studies.</p></sec><sec id="sec9"><title>Author contributions</title><p id="p0545">Writing, review, and/or revision of the manuscript: J.A. Graphical abstract/figure generation: J.A. Development of the methodology: T.T. Utilization and initiation of the model: J.A. and T.T. Funding and manuscript review: S.L.H.</p></sec><sec sec-type="COI-statement" id="sec10"><title>Declaration of interests</title><p id="p0550">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Almazan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Turapov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kircher</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>K.</given-names></name><name name-style="western"><surname>Medellin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Field</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Parkman</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Colman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coma</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Combined Inhibition of Focal Adhesion Kinase and RAF/MEK Elicits Synergistic Inhibition of Melanoma Growth and Reduces Metastases</article-title><source>CR Med</source><volume>6</volume><year>2025</year><object-id pub-id-type="publisher-id">101943</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2025.101943</pub-id><pub-id pub-id-type="pmcid">PMC11866499</pub-id><pub-id pub-id-type="pmid">39922199</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Chaichana</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chaichana</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Chaichana</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chaichana</surname><given-names>K.L.</given-names></name></person-group><part-title>Diagnosis and Treatment Options for Brain Metastasis of Melanoma</part-title><source>Treatment of Metastatic Melanoma</source><year>2011</year><publisher-name>IntechOpen</publisher-name><fpage>47</fpage><lpage>65</lpage></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Kircher</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Trombetti</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Silvis</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Parkman</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Angel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Stehn</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Strain</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Grossmann</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis</article-title><source>Mol. Cancer Res.</source><volume>17</volume><year>2019</year><fpage>1787</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">31138602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1541-7786.MCR-18-1372</pub-id><pub-id pub-id-type="pmcid">PMC6726552</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>C.-P.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weaver Ohler</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bonomi</surname><given-names>C.</given-names></name><name name-style="western"><surname>El Meskini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Graff-Cherry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feigenbaum</surname><given-names>L.</given-names></name><name name-style="western"><surname>T&#252;ting</surname><given-names>T.</given-names></name><name name-style="western"><surname>Van Dyke</surname><given-names>T.</given-names></name><etal/></person-group><article-title>&#8220;Glowing Head&#8221; Mice: A Genetic Tool Enabling Reliable Preclinical Image-Based Evaluation of Cancers in Immunocompetent Allografts</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e109956</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0109956</pub-id><pub-id pub-id-type="pmcid">PMC4219677</pub-id><pub-id pub-id-type="pmid">25369133</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Anandasabapathy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Bertolotto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ceol</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Burd</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bosenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merlino</surname><given-names>G.</given-names></name></person-group><article-title>Melanoma models for the next generation of therapies</article-title><source>Cancer Cell</source><volume>39</volume><year>2021</year><fpage>610</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">33545064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2021.01.011</pub-id><pub-id pub-id-type="pmcid">PMC8378471</pub-id></element-citation></ref></ref-list></back></article>